Welcome to our dedicated page for PANACEA LIFE SCIENCE HLD news (Ticker: PLSH), a resource for investors and traders seeking the latest updates and insights on PANACEA LIFE SCIENCE HLD stock.
Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) is a forward-thinking company dedicated to enhancing human and animal health through natural wellness products. The firm operates a state-of-the-art, 51,000 square foot cGMP facility in Golden, Colorado. Panacea specializes in the manufacturing, research, and development of a diverse range of products, including nutraceuticals, cannabinoids, mushrooms, kratom, and other plant-based ingredients.
Panacea began its journey as a producer of industrial hemp cannabinoid products and has since broadened its portfolio to include a wide array of health and wellness solutions. The company’s offerings range from soft gels, liquid fills, and topical lotions to dietary supplements and unique skin moisturizers. They aim to benefit everyday health and well-being.
The company is at the forefront of exploring the potential of functional mushrooms. Dividing the mushroom market into three segments—functional mushrooms, schedule one mushrooms containing psilocybin, and Amanita Muscaria mushrooms—Panacea is developing new products targeted at specific health conditions. Working closely with Colorado State University, they are creating analytical methods to measure active components and identify heavy metals in various mushroom species, ensuring safety and efficacy in their supplements.
Panacea also places significant emphasis on blending natural ingredients to enhance product effectiveness. Their collaborations extend to creating performance and endurance-enhancing compounds that incorporate ingredients like ginseng, aiming to boost athletic performance.
The company is committed to keeping shareholders and customers informed about their progress and new product developments. Their recent collaboration with Colorado State University and ongoing clinical trials highlight their dedication to advancing natural health solutions. Panacea Life Sciences Holdings, Inc. continues to expand its market presence and product lines, positioning itself as a leader in the health and wellness sector.
Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) has announced a distribution agreement with C.A.G. Global to expand its CBD product line into Guyana, an emerging market with significant growth potential following a major oil discovery. The launch is set for May 2023, targeting Georgetown's pharmacies and convenience stores to serve its 300,000 residents. The company aims to align its CBD wellness products with Guyana's governmental push for a greener economy. Panacea develops and manufactures its products in-house, ensuring they are affordable for local consumers. This strategic move highlights Panacea's commitment to global expansion and positions it to benefit from the projected growth of the CBD market in Guyana.
Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) announced a remarkable growth trajectory, achieving over 100% revenue growth since launching its contract manufacturing in June 2022. The company has also seen a double-digit increase in its customer base over the past six months. A significant contributor to this expansion is the production of Vegan Softgel products, which now represent 65% of ongoing projects. As a cGMP certified manufacturer, Panacea focuses on innovative, plant-based formulations, fostering trust among clients while addressing consumer skepticism toward lab-developed drugs.
Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) announced the execution of a letter of intent to acquire N7 Enterprises, Inc. The acquisition will involve issuing common shares of PLSH to N7's shareholders. N7 Enterprises operates kava and kratom lounges in Florida and distributes related products, generating $4.1 million in revenue and over $1 million in net income for 2022. CEO Leslie Buttorff emphasized that this acquisition will enhance PLSH's market penetration in the health and wellness sector. The completion of the acquisition is subject to due diligence and other conditions and is not expected to result in a change of control for PLSH.
Panacea Life Sciences (OTCQB:PLSH) celebrates one year of collaboration with Colorado State University’s Cannabinoid Research Center (CRC). The partnership aims to address industry challenges linked to cannabinoids. Notably, the CRC, funded by a $1.5 million contribution, has developed methods for removing contaminants from hemp and is advancing the study of minor cannabinoids. Significant clinical trials are underway, examining CBD's effects on Alzheimer's and irritable bowel syndrome. The CRC plans to expand its research into other cannabinoids and related health issues, aiming for sustainable practices.
On August 17, 2022, Panacea Life Sciences Holdings (OTCQB: PLSH) announced its expansion into the nutraceutical market with a focus on softgel manufacturing. The company received eight purchase orders valued at approximately $500,000, expected to boost revenues for the remainder of the fiscal year. Panacea's facility in Colorado, certified in cGMP, can produce up to 1 million softgels daily. The investment in equipment and staffing reflects a commitment to becoming a leading vegan softgel provider in the U.S., highlighting growing demand for quality manufacturing in the cannabinoid industry.
Panacea Life Sciences Holdings (OTCQB: PLSH) announced the launch of its new CBDA Oil Drops, aimed at providing potential preventative benefits against SARS-CoV-2 and addressing Long COVID effects. The product contains 50mg of CBDA per serving, along with Zinc and Vitamin D, enhancing immune support. Preliminary studies suggest that CBDA and CBGA may inhibit the virus's ability to infect cells. Panacea's research initiatives at Colorado State University will focus on further understanding the benefits of cannabinoids. The company is committed to developing effective health solutions derived from hemp.
Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) will participate in the White Label World Expo in Las Vegas on May 25-26, 2022. The company aims to highlight its proprietary vegan softgel manufacturing capabilities and launch a new pet treat line.
Panacea is capable of producing 1.5 million softgels daily and offers comprehensive services from R&D to manufacturing. The Expo serves as a platform for global leaders and businesses in the health and wellness industry, reinforcing Panacea's position in the cannabinoid market.
Panacea Life Sciences (OTCQB:PLSH) has announced its new vegan softgel manufacturing capabilities, aimed at satisfying the growing demand for clean, natural alternatives to animal products. After over two years of research, the company has developed a proprietary vegan formula using tapioca starch, which is Non-GMO Project verified. The production capacity exceeds 1 million softgels per day, enhancing customer offerings in the CBD and nutraceutical markets. Panacea will showcase these innovations at the White Label World Expo in Las Vegas on May 25-26, 2022.
Panacea Life Sciences Holdings (OTCQB:PLSH) announced CEO Leslie Buttorff's participation in the Q2 Investor Summit Group on May 3-4, 2022, in New York City. Buttorff will present the company's growth roadmap during a session on May 3rd at 1:15 PM ET. The conference, aimed at connecting smallcap and microcap companies with investors, will also offer 1x1 meetings for qualified investors. Panacea is focused on cannabinoid-based products for various medical conditions and aims to rank among the top 10 U.S. firms in revenue and brand.
Panacea Life Sciences (OTCQB:PLSH) announced the formation of its Scientific Advisory Board, consisting of six experts in cannabinoid research. This board aims to enhance the company's efforts in developing biomedical cannabinoid products for humans and pets. The team will provide guidance on product validation, study design, and more, leveraging their extensive experience across multiple fields including dermatology and veterinary medicine. The initiative underscores Panacea's commitment to science-driven product development as it seeks to differentiate itself in the cannabinoid market.
FAQ
What is the current stock price of PANACEA LIFE SCIENCE HLD (PLSH)?
What is the market cap of PANACEA LIFE SCIENCE HLD (PLSH)?
What does Panacea Life Sciences Holdings, Inc. specialize in?
Where is Panacea Life Sciences Holdings, Inc. located?
What are the main products offered by Panacea?
How is Panacea involved in the mushroom market?
What is the company's approach to product development?
What are the benefits of Panacea's functional mushroom products?
Does Panacea blend natural ingredients in their products?
How does Panacea ensure the safety of their products?
What recent collaborations has Panacea announced?
How can I stay updated on Panacea's latest developments?
